Achieve Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Tables)

Common Stock (Tables)

9 Months Ended

Sep. 30, 2012


	Number of			Weighted
	Optioned			Average
	Common			Exercise
	Shares			Price
	#			$
Balance, December 31, 2011		766,328			9.82
Option grants		157,850			13.02
Option expirations		(12,309	)		9.10
Option exercises		(116,834	)		3.94
Option forfeitures		(4,541	)		15.26

Balance, September 30, 2012		790,494			11.31

Summary of fair value option award


	Nine months ended September 30,
	2012			2011
Risk-free interest rates		0.96	%		2.16	%
Expected dividend yield		0	%		0	%
Expected life		6 years			6 years
Expected volatility		95.47	%		76.0	%

Summary of share-based compensation expense


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2012		2011		2012		2011
	$		$		$		$
Research and development		243		250		671		493
General and administrative		338		62		939		373

Total share-based compensation		581		312		1,610		866

Summary of restricted stock award activity


	2012					2011
	Stock Awards #			Weighted- Average Grant Date Fair Value $		Stock Awards #		Weighted- Average Grant Date Fair Value $
Outstanding January 1		—			—		—		—
Granted		172,685			13.03		—		—
Vested		—			—		—		—
Forfeited and expired		(8,000	)		13.00		—		—

Outstanding September 30		164,685			13.03		—		—

Summary of fair value of warrants issued


	Nine Months Ended September 30,
	2012			2011
Risk-free interest rates		0.32	%		0.71	%
Expected dividend yield		0	%		0	%
Expected life		3.06 years			4.06 years
Expected volatility		50.67	%		76.00	%

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details